Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

Phase I Clinical Study on the Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05681000
• Other study ID #: BG02-2201
• Status: Recruiting
• Phase: Phase 1
• Start date: June 9, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: December 2022
• Source: Beijing Biostar Pharmaceuticals Co., Ltd.
• Contact: RONGGUO QIU, PhD
• Phone: 01186-56315388
• Email: rqiu2001[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to evaluate the safety and tolerability of Utidelone Capsule in patients with advanced solid tumors and determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). The secondary objectives are to evaluate the pharmacokinetic profile of Utidelone Capsule in patients with advanced solid tumors, preliminarily assess the anti-tumor activity of Utidelone Capsule in patients with advanced solid tumors via objective radiologic tumor response using RECIST 1.1, and to recommend the dose and dosage regimen for subsequent clinical trials.

Description:

At least 4 dose cohorts are planned, and 16-28 cases are expected. 1. Cohort 1 and 2: 2 cases are planned for each. 2. Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: December 31, 2024
• Est. primary completion date: April 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to sign a written informed consent;

2. Patients with histologic or pathologic documentation of incurable, locally advanced, or metastatic solid tumors for which standard therapies are not available, no longer effective, and not tolerated, and for those patients who have declined the standard therapies;

3. Male or female subjects aged =18, with ECOG performance status scored 0-1;

4. Expected survival time = 12 weeks;

5. Adequate organ and marrow function as defined below:

1. neutrophil count (ANC) = 1.5 × 109/L

2. platelet count (PLT) = 100 × 109/L

3. hemoglobin = 9 g/dL

4. total bilirubin (TBIL) = 1.5 × upper limit of normal (ULN)

5. alanine transaminase (ALT) = 2.5 × ULN

6. aspartate transaminase (AST) = 2.5 × ULN

7. Creatinine clearance = 60 mL/min

6. Female patients of childbearing potential must have negative serum or urine pregnancy test at screening;

7. Sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 30 days or till next chemotherapy cycle. Cessation of birth control after this point should be discussed with a responsible physician. Investigator will discuss with patient on the above points and the patient agreement will be documented in the source document. The investigator should ensure that the patient is using an effective method of avoiding pregnancy as per protocol. In case of Male patients: Either patient partners or patients themselves must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days or till next chemotherapy cycle.

Exclusion Criteria:

1. Patients who have received non-investigational anti-tumor therapies (such as chemotherapy, radiotherapy, immunotherapy, biological therapy or traditional Chinese medicine treatment) within 2 weeks prior to study drug administration;

2. Patients with hypersensitivity reaction caused by previous anti-microtubule drugs;

3. Patients who have known brain metastasis; patients whose CNS metastases have been treated by surgery or radiotherapy, who are no longer on corticosteroids, and who are neurologically stable are eligible;

4. Patients with a history of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or ECG abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder. Atrial fibrillation is allowed if rate is controlled;

5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements;

6. Patients with baseline QTc interval > 470 msec;

7. Patients with known history of human immunodeficiency virus (HIV) infection with an exception that if they have not had an opportunistic infection within the past 12 months, they are eligible;

8. Patients who are HBV DNA positive;

9. Patients with pre-existing > Grade 1 peripheral sensory neuropathy (NCI CTCAE 5.0) ;

10. Patients who still experience = Grade 2 acute toxicities caused by previous anti-tumor therapies (e.g. chemotherapy, radiotherapy, immunotherapy, biological therapy or TCM treatment) prior to enrollment (NCI-CTCAE 5.0, except alopecia);

11. Patients who have undergone any major surgery or have major trauma within 4 weeks prior to administration of the investigational product or are expected to undergo major surgery during the first cycle of treatment;

12. Patients who have received other investigational treatments within 4 weeks prior to administration of the investigational product.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• Utidelone Capsule
At least 4 dose cohorts are planned, and 16-28 cases are expected. Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle. Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively.

Locations

Country	Name	City	State
United States	University of Southern California	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Biostar Pharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose, MTD	The maximum tolerated dose (MTD) is defined as the highest dose tested in which none or only one patient experienced DLT attributable to the study drug(s), when 6 patients were treated at that dose and are evaluable for toxicity. The MTD is one dose level below the lowest dose tested in which 2 or more patients experienced DLT attributable to the study drug(s).	12 months
Primary	Dose-Limiting Toxicity, DLT	DLT is observed during Cycle 1 in the dose escalation trial. Any toxicity meeting the criteria outlined in the protocol, at least possibly related to study drug (i.e. definitely, probably, or possibly attributed), will be considered a DLT.	12 months
Secondary	Maximum (or peak) serum concentration-Cmax	Cmax of Utidelone Capsule	12 months
Secondary	Time to peak drug concentration-Tmax	Tmax of Utidelone Capsule	12 months
Secondary	the area under the concentration-time curve from dosing (time 0) to time t-AUC0-t	the AUC0-t of Utidelone Capsule	12 months
Secondary	the time required for plasma concentration of a drug to decrease by 50%-t1/2	the t1/2 of Utidelone Capsule	12 months
Secondary	Objective Response Rate-ORR	The percentage of patients who have a partial response or complete response to the treatment within a certain period of time.	12 months
Secondary	Recommended Phase II Dose (RP2D)	To recommend the dose and dose regimen for subsequent clinical trials.	12 months